4.6 Article

Neutrophil Extracellular Traps That Are Not Degraded in Systemic Lupus Erythematosus Activate Complement Exacerbating the Disease

Journal

JOURNAL OF IMMUNOLOGY
Volume 188, Issue 7, Pages 3522-3531

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1102404

Keywords

-

Categories

Funding

  1. Swedish Research Council [K2009-68X-14928-06-3, 2008-2201]
  2. Swedish Foundation for Strategic Research
  3. Foundation of Osterlund
  4. Foundation of Kock
  5. Foundation of Crafoord
  6. Foundation of King Gustav V's 80th Anniversary
  7. Swedish Rheumatism Association
  8. Swedish Society of Medicine
  9. Knut and Alice Wallenberg
  10. Inga Britt and Arne Lundberg
  11. Foundation of the National Board of Health and Welfare
  12. Skane University Hospital

Ask authors/readers for more resources

Ongoing inflammation including activation of the complement system is a hallmark of systemic lupus erythematosus (SLE). Antimicrobial neutrophil extracellular traps (NETs) are composed of secreted chromatin that may act as a source of autoantigens typical for SLE. In this study, we investigated how complement interacts with NETs and how NET degradation is affected by complement in SLE patients. We found that sera from a subset of patients with active SLE had a reduced ability to degrade in vitro-generated NETs, which was mostly restored when these patients were in remission. Patients that failed to degrade NETs had a more active disease and they also displayed lower levels of complement proteins C4 and C3 in blood. We discovered that NETs activated complement in vitro and that deposited C1q inhibited NET degradation including a direct inhibition of DNase-I by C1q. Complement deposition on NETs may facilitate autoantibody production, and indeed, Abs against NETs and NET epitopes were more pronounced in patients with impaired ability to degrade NETs. NET-bound autoantibodies inhibited degradation but also further increased C1q deposition, potentially exacerbating the disease. Thus, NETs are a potent complement activator, and this interaction may play an important role in SLE. Targeting complement with inhibitors or by removing complement activators such as NETs could be beneficial for patients with SLE. The Journal of Immunology, 2012, 188: 3522-3531.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available